ImmunoPrecise Antibodies Ltd. (IPA )

Currency in USD Disclaimer
$1.73 -$0.01 (-0.57%)
Closed 07/18/2025
$1.65
$1.82
$0.27
$2.32

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol IPA
  • Company ImmunoPrecise Antibodies Ltd.
  • Price $1.73
  • Changes Percentage -0.57
  • Change -0.01
  • Day Low $1.65
  • Day High $1.82
  • Year High $2.32
  • Year Low $0.27
  • Market Cap $79,173,654
  • Price Avg 50 EMA (D) $0.92
  • Price Avg 200 EMA (D) $0.57
  • Exchange NASDAQ
  • Volume 1,135,239
  • Average Volume 2,232,796
  • Open $1.77
  • Previous Close $1.74
  • EPS -1.23
  • PE -1.41
  • Earnings Announcement 2025-07-29 12:30:00
  • Shares Outstanding $45,765,118

Company brief: IMMUNOPRECISE ANTIBODIES LTD. (IPA )

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

IPA Corporation News

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

July 16, 2025 at 12:05 pm ET

businesswire.com -- AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-gen...

Income Statement